Soros Fund Management LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 175,000 shares of the life sciences company's stock, valued at approximately $22,822,000. Soros Fund Management LLC owned about 0.11% of Illumina as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently modified their holdings of the company. Industrial Alliance Investment Management Inc. acquired a new position in shares of Illumina in the second quarter worth approximately $34,000. Massmutual Trust Co. FSB ADV boosted its stake in shares of Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock valued at $56,000 after purchasing an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in Illumina during the second quarter worth $61,000. Private Trust Co. NA lifted its holdings in Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after buying an additional 212 shares during the period. Finally, Mizuho Securities Co. Ltd. bought a new stake in Illumina during the second quarter valued at $63,000. Institutional investors and hedge funds own 89.42% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on ILMN. Leerink Partners boosted their price objective on Illumina from $160.00 to $200.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. UBS Group raised their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Stephens boosted their target price on shares of Illumina from $170.00 to $184.00 and gave the company an "overweight" rating in a research report on Tuesday, November 12th. Daiwa America upgraded Illumina to a "strong-buy" rating in a research note on Friday, August 16th. Finally, Hsbc Global Res raised shares of Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price target for the company in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $164.00.
Check Out Our Latest Stock Report on Illumina
Illumina Price Performance
NASDAQ ILMN traded up $0.53 during trading on Friday, reaching $140.44. The company's stock had a trading volume of 289,086 shares, compared to its average volume of 2,011,654. The stock has a market capitalization of $22.27 billion, a PE ratio of -14.23 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The firm has a fifty day moving average of $142.90 and a 200 day moving average of $126.66. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period in the previous year, the business posted $0.33 earnings per share. Illumina's revenue for the quarter was down 3.5% on a year-over-year basis. Analysts expect that Illumina, Inc. will post 4.11 EPS for the current fiscal year.
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Stories
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
